These improvements preluded to the first unambiguous successful clinicalapplications of gene therapy in patients affected with X-linked SCID (SCIDX-1),ADA-SCID, and Wiskott-Aldrich syndrome (WAS) 10– 13 ( Figure 1). This evidence concerns the gene ADA and Wiskott-Aldrich syndrome.